Skip to content
value.today
TriSalus Life Sciences, Inc. logo

TriSalus Life Sciences, Inc.

TLSI
$234 Mmarket cap on Oct 28, 2026+6.6% since Jan 2024
Compare
World rank
#15,689
Revenue
$45 M
For year ending December-2025
Net income
$-39 M
-86.9% margin
SEC filing
Employees
102
As of December 31, 2025
SEC filing

TriSalus Life Sciences, Inc. in brief

TriSalus Life Sciences, Inc. is a listed company in the Healthcare sector, based in Westminster, Colorado, USA. Its market value was $234 M on 28 October 2026, which makes it the 15,689th largest listed company in the world and the 3,060th largest in the USA on this site. In the year to December 2025 it had sales of $45 M and a net loss of $39 M. It employs about 102 people and Mary T. Szela is its chief executive. Its shares trade under the symbol TLSI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About TriSalus Life Sciences, Inc.

We are a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. Our ultimate goal is to transform the treatment paradigm for patients battling solid tumors. We have developed an innovative technology designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) off target delivery. Nelitolimod, specifically, combined with our technology aims to address the immunosuppressive properties of tumor immune cells in liver, pancreas and other solid tumors. By systematically addressing these barriers, we aim to improve response to therapies and to enable improved patient outcomes.

From the company's annual report filed with the US SEC: read the report

TriSalus Life Sciences, Inc. timeline

4 events, 2020–2025
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering as MedTech Acquisition Corporation
    Final prospectus filed with the SEC on 21 December 2020; shares registered for exchange trading on 16 December 2020. The blank-check company later merged with the business that carries the name today.
  4. 2023
  5. ✎
    Renamed TriSalus Life Sciences, Inc.
    Formerly MedTech Acquisition Corporation.
  6. 2025
  7. 💰
    Record revenue of $45 million
    FY2025, the highest of the 4 years on record.

Events of TriSalus Life Sciences, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$87 M$175 M$262 M$350 M202420252026

World rank over time

▲ up 4,664 places since 2023
2023-07-30: #20387#20,38720232024-01-05: #17406#17,40620242026-03-08: #8827#8,82720262026-08-01: #13922#13,92220262026-10-13: #15485#15,48520262026-10-28: #15723#15,7232026

Rank in USA: #3,981 (Jul 2023) · #3,176 (Jan 2024) · #1,659 (Mar 2026) · #2,811 (Aug 2026) · #2,994 (Oct 2026) · #3,064 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
5.1×
Price / book
—
Free cash flow yield
-8.1%
Net margin (TTM)
-56.6%
Operating margin
-59.7%
Return on equity
—
Liabilities / assets
195.8%
Net debt
$13M
Revenue growth
+53.4%
R&D / revenue
33.1%
Revenue per employee
$443 K
Profit per employee
$-385 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $5M—FY21Fiscal year ending Dec 2022: revenue $12M, net income $-47M$12MFY22Fiscal year ending Dec 2023: revenue $19M, net income $-59M$19MFY23Fiscal year ending Dec 2024: revenue $29M, net income $-30M$29MFY24Fiscal year ending Dec 2025: revenue $45M, net income $-39M$45MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$45M+53.4%$-27M$-39M-86.9%
Dec 2024$29M+59.0%$-36M$-30M-102.1%
Dec 2023$19M+49.3%$-54M$-59M-320.7%
Dec 2022$12M—$-36M$-47M-380.6%
Dec 2021——$-3M$5M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-18M$1M$-19M$-1.84—
Dec 2024$-41M$0M$-41M$-1.31—
Dec 2023$-51M$1M$-51M$-6.77—
Dec 2022$-32M$1M$-33M$-161.55—
Dec 2021$-2M————

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$46M
Net income, trailing 12 months
$-26M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $8M, net income $-10M$8MDec ’24Three months to Mar 2025: revenue $9M, net income $-10M$9MMar ’25Three months to Jun 2025: revenue $11M, net income $-8M$11MJun ’25Three months to Sep 2025: revenue $12M, net income $-11M$12MSep ’25Three months to Dec 2025 (from the annual report): revenue $13M, net income $-10M$13MDec ’25Three months to Mar 2026: revenue $9M, net income $2M$9MMar ’26Three months to Jun 2026: revenue $11M, net income $-9M$11MJun ’26Three months to Sep 2026: revenue $13M, net income $-9M$13MSep ’26

Latest quarter to Sep 2026: revenue $13M (+11.3% on a year earlier), net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of TriSalus Life Sciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$45 M
Operating income
$-27 M
Net income
$-39 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$35 M
Total liabilities
$69 M
Total equity
$-34 M

As of December-2025

Top 82 institutional investors in TriSalus Life Sciences, Inc.#

As of Sep 30, 2026
82 institutions held 22.2 M shares (about 36.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 28.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in TriSalus Life Sciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1First Light Asset Management, LLC7,416,274+863,783 (+13.18%)12.02%$32 MNov 16, 2026
2BlackRock, Inc.2,611,150-48,068 (-1.81%)4.23%$11 MNov 13, 2026
3Vanguard Capital Management LLC1,720,671-8,714 (-0.50%)2.79%$7 MNov 13, 2026
4Cerity Partners LLC1,605,414+1,876 (+0.12%)2.60%$7 MNov 13, 2026
5Geode Capital Management, LLC1,123,372-66,695 (-5.60%)1.82%$5 MNov 6, 2026
6Gilder Gagnon Howe & Co LLC818,936-31,145 (-3.66%)1.33%$4 MNov 16, 2026
7State Street Corp668,897+57,934 (+9.48%)1.08%$3 MNov 12, 2026
8Kennedy Capital Management LLC625,690+149,429 (+31.38%)1.01%$3 MNov 13, 2026
9Thompson Siegel & Walmsley LLC529,534-7,000 (-1.30%)0.86%$2 MNov 5, 2026
10Nantahala Capital Management, LLC500,000-1,500,000 (-75.00%)0.81%$2 MNov 13, 2026
11White Pine Capital LLC497,186-50,391 (-9.20%)0.81%$2 MNov 9, 2026
12Morgan Stanley418,014+16,200 (+4.03%)0.68%$2 MNov 13, 2026
13Northern Trust Corp351,899-27,673 (-7.29%)0.57%$2 MNov 16, 2026
14Invesco Ltd.351,753+295,379 (+523.96%)0.57%$2 MNov 12, 2026
15Vanguard Portfolio Management LLC308,945-20,519 (-6.23%)0.50%$1 MNov 13, 2026
16Vanguard Fiduciary Trust Co306,101-14,855 (-4.63%)0.50%$1 MNov 13, 2026
17Perkins Capital Management Inc297,991+62,890 (+26.75%)0.48%$1 MNov 2, 2026
18Bank Of America Corp /de/222,323+16,981 (+8.27%)0.36%$1 MNov 16, 2026
19Royce & Associates LP200,0600 (0.00%)0.32%$1 MNov 9, 2026
20UBS Group AG176,920-46,127 (-20.68%)0.29%$1 MNov 10, 2026
21Charles Schwab Investment Management Inc158,987+51,042 (+47.29%)0.26%$1 MNov 16, 2026
22Goldman Sachs Group Inc115,354+32,956 (+40.00%)0.19%$0 MNov 16, 2026
23AQR Capital Management LLC114,161-3,816 (-3.23%)0.18%$0 MNov 16, 2026
24Bank of New York Mellon Corp99,093-12,441 (-11.15%)0.16%$0 MNov 5, 2026
25Corient Private Wealth LP95,002-52,150 (-35.44%)0.15%$0 MNov 16, 2026
Show all 82: investors 26 to 82
Institutional investors 26 to 82 in TriSalus Life Sciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26CWA Asset Management Group, LLC72,0000 (0.00%)0.12%$0 MOct 19, 2026
27Bridgeway Capital Management, LLC68,406-1,094 (-1.57%)0.11%$0 MNov 16, 2026
28Nuveen, LLC66,896+2,998 (+4.69%)0.11%$0 MNov 10, 2026
29Empowered Funds, LLC63,906New0.10%$0 MNov 13, 2026
30MSD Partners, L.P.39,9990 (0.00%)0.06%$0 MNov 16, 2026
31Price T Rowe Associates Inc /MD/39,3350 (0.00%)0.06%$0 MNov 16, 2026
32Deutsche Bank AG\38,623-9,900 (-20.40%)0.06%$0 MNov 6, 2026
33HighMark Wealth Management LLC38,300-10,000 (-20.70%)0.06%$0 MNov 17, 2026
34Millennium Management LLC36,140New0.06%$0 MNov 16, 2026
35SEI Investments Co31,8090 (0.00%)0.05%$0 MNov 10, 2026
36Quadrature Capital Ltd30,775New0.05%$0 MNov 13, 2026
37Rhumbline Advisers29,342-779 (-2.59%)0.05%$0 MNov 10, 2026
38Connecticut Wealth Management, LLC22,3030 (0.00%)0.04%$0 MOct 13, 2026
39Jpmorgan Chase & Co22,139+1,931 (+9.56%)0.04%$0 MNov 12, 2026
40MetLife Investment Management, LLC22,061-8,352 (-27.46%)0.04%$0 MNov 16, 2026
41Provenance Wealth Advisors, LLC21,737New0.04%$0 MOct 30, 2026
42MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.21,233-840 (-3.81%)0.03%$0 MNov 16, 2026
43XTX Topco Ltd19,374+6,141 (+46.41%)0.03%$0 MNov 16, 2026
44Virtu Financial LLC18,230New0.03%$0 MNov 17, 2026
45Barclays PLC17,243+8,596 (+99.41%)0.03%$0 MNov 6, 2026
46Police & Firemen's Retirement System of New Jersey16,2000 (0.00%)0.03%$0 MNov 9, 2026
47Russell Investments Group, Ltd.15,727+286 (+1.85%)0.03%$0 MNov 6, 2026
48Cambridge Investment Research Advisors, Inc.15,5540 (0.00%)0.03%$0 MNov 2, 2026
49Vanguard Global Advisers, LLC15,486+218 (+1.43%)0.03%$0 MNov 13, 2026
50Wells Fargo & Company/mn14,477-30,251 (-67.63%)0.02%$0 MNov 16, 2026
51D. E. Shaw & Co., Inc.12,494New0.02%$0 MNov 16, 2026
52New York State Common Retirement Fund11,0950 (0.00%)0.02%$0 MNov 17, 2026
53BNP Paribas Financial Markets10,572+3,373 (+46.85%)0.02%$0 MNov 12, 2026
54Arax Advisory Partners5,991+144 (+2.46%)0.01%$0 MNov 12, 2026
55Legal & General Group Plc4,6660 (0.00%)0.01%$0 MNov 16, 2026
56Ameritas Investment Partners, Inc.4,3500 (0.00%)0.01%$0 MNov 13, 2026
57Tower Research Capital LLC (TRC)3,248+130 (+4.17%)0.01%$0 MNov 16, 2026
58FMR LLC2,472-86 (-3.36%)0.00%$0 MNov 10, 2026
59Royal Bank Of Canada2,332+498 (+27.15%)0.00%$0 MNov 16, 2026
60Citigroup Inc2,202-20,313 (-90.22%)0.00%$0 MNov 4, 2026
61PNC Financial Services Group, Inc.1,956+1,813 (+1267.83%)0.00%$0 MNov 6, 2026
62Sterling Capital Management LLC1,572+1,404 (+835.71%)0.00%$0 MOct 22, 2026
63Hoertkorn Richard Charles6680 (0.00%)0.00%$0 MNov 4, 2026
64JDM Financial Group LLC5300 (0.00%)0.00%$0 MNov 17, 2026
65California State Teachers Retirement System3930 (0.00%)0.00%$0 MNov 13, 2026
66Allworth Financial LP297-7 (-2.30%)0.00%$0 MNov 17, 2026
67Global Retirement Partners, LLC293New0.00%$0 MNov 10, 2026
68EverSource Wealth Advisors, LLC226-14 (-5.83%)0.00%$0 MNov 4, 2026
69SJS Investment Consulting Inc.213+201 (+1675.00%)0.00%$0 MOct 26, 2026
70GAMMA Investing LLC193New0.00%$0 MOct 8, 2026
71DiPaolo Financial Group, Inc.170New0.00%$0 MNov 12, 2026
72Clearstead Advisors, LLC1000 (0.00%)0.00%$0 MNov 6, 2026
73Signaturefd, LLC1000 (0.00%)0.00%$0 MOct 23, 2026
74Essential Partners LLC92-3 (-3.16%)0.00%$0 MOct 14, 2026
75Farther Finance Advisors, LLC80+2 (+2.56%)0.00%$0 MOct 8, 2026
76True Wealth Design, LLC66-12 (-15.38%)0.00%$0 MOct 13, 2026
77Fortitude Family Office, LLC280 (0.00%)0.00%$0 MOct 14, 2026
78Root Financial Partners, LLC16New0.00%$0 MOct 21, 2026
79SBI Securities Co., Ltd.12New0.00%$0 MOct 22, 2026
80Rothschild Investment LLC9-60 (-86.96%)0.00%$0 MNov 10, 2026
81IFP Advisors, Inc7-44 (-86.27%)0.00%$0 MOct 16, 2026
82Caitong International Asset Management Co., Ltd2+1 (+100.00%)0.00%$0 MOct 29, 2026

Mutual funds holding TriSalus Life Sciences, Inc.#

59 funds hold shares worth $24 M (about 8.8% of the company). Since their previous reports 46 added shares and 14 sold, buying $2 M net.
Mutual funds holding TriSalus Life Sciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.14 M$5 M1.9%<0.01%+27%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.12 M$5 M1.8%<0.01%+73%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.545,765$2 M0.88%<0.01%+41%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC521,754$2 M0.85%<0.01%+90%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors450,180$2 M0.73%0.01%+712%Jun 30, 2026
🇺🇸 Royce Smaller-Companies Growth FundRoyce & Associates, LP200,000$1 M0.32%0.38%no changeJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors160,188$1 M0.26%0.05%+126%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC189,776$1 M0.31%<0.01%+0.3%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.116,669$1 M0.19%<0.01%+97%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.143,142$0 M0.23%<0.01%−4.6%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC89,608$0 M0.15%<0.01%+224%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC65,000$0 M0.11%0.20%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC63,898$0 M0.10%<0.01%+75%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.56,111$0 M0.09%<0.01%+149%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC68,501$0 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC49,491$0 M0.08%<0.01%+60%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC44,692$0 M0.07%0.01%+776%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC53,913$0 M0.09%<0.01%+6.2%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation35,700$0 M0.06%<0.01%+130%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC39,480$0 M0.06%<0.01%+15%May 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.24,964$0 M0.04%<0.01%+153%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC22,914$0 M0.04%<0.01%+88%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.21,096$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.20,654$0 M0.03%<0.01%−49%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC17,243$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC14,339$0 M0.02%<0.01%+87%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.17,689$0 M0.03%<0.01%+4.4%May 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.11,300$0 M0.02%<0.01%+13%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC10,760$0 M0.02%0.02%+116%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC10,619$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC10,264$0 M0.02%<0.01%+63%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS9,775$0 M0.02%<0.01%+106%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company11,389$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.7,527$0 M0.01%<0.01%+83%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.7,228$0 M0.01%<0.01%+109%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC7,188$0 M0.01%<0.01%+864%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC6,774$0 M0.01%<0.01%+86%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC6,174$0 M0.01%<0.01%+92%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC5,614$0 M<0.01%<0.01%+64%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.6,659$0 M0.01%<0.01%+2.9%May 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS4,450$0 M<0.01%<0.01%+85%Jul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC4,408$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,350$0 M<0.01%<0.01%+167%Jun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC4,339$0 M<0.01%0.01%+1608%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC4,030$0 M<0.01%<0.01%+595%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC4,030$0 M<0.01%<0.01%+595%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,824$0 M<0.01%<0.01%+189%Jun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,665$0 M<0.01%<0.01%+404%Jul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC3,620$0 M<0.01%<0.01%+82%Jun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS3,534$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,227$0 M<0.01%<0.01%+155%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.2,257$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,397$0 M<0.01%<0.01%+110%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,321$0 M<0.01%<0.01%+0.4%May 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC998$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,044$0 M<0.01%<0.01%−44%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,033$0 M<0.01%<0.01%−45%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC666$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC209$0 M<0.01%<0.01%+48%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 59 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at TriSalus Life Sciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$3.6 M
13 purchases, 6 insiders
Sold, 12 months
$141 K
19 sales, 5 insiders
Net, 12 months
$3.5 M
open market only
Insiders on file
22
since
$1.8 M-$134 K$0Aug 2024: bought $0 (0 trades), sold $50 (1 trades)Aug 24Sep 2024: bought $100 K (4 trades), sold $0 (0 trades)Oct 2024: bought $0 (0 trades), sold $1 K (1 trades)OctNov 2024: bought $70 K (3 trades), sold $0 (0 trades)Dec 2024: bought $250 K (1 trades), sold $111 K (1 trades)DecJan 2025: bought $389 K (7 trades), sold $0 (0 trades)Feb 2025: bought $34 K (1 trades), sold $0 (0 trades)FebMay 2025: bought $0 (0 trades), sold $104 K (4 trades)Feb 2026: bought $1.7 M (6 trades), sold $0 (0 trades)FebMar 2026: bought $0 (0 trades), sold $134 K (14 trades)May 2026: bought $1.8 M (6 trades), sold $1 K (1 trades)MayOct 2026: bought $0 (0 trades), sold $4 K (3 trades)Nov 2026: bought $112 K (1 trades), sold $1 K (1 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
TriSalus Life Sciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Richard MarshakChief Commercial OfficerSell-544$2.430$1 K127,450Form 4
filed Mats WahlstromDirectorBuy+50,000$2.240$112 K197,555Form 4
filed Jennifer StevensChief Regulatory OfficerSell-316$4.390$1 K123,794Form 4
filed Richard MarshakChief Commercial OfficerSell-325$4.390$1 K127,994Form 4
filed Bryan F. CoxChief of ResearchSell-296$4.390$1 K162,805Form 4
filed Mary T. SzelaCEO and President, DirectorShares withheld for tax-2,693$4.380$12 K1.07 MForm 4
filed David PatienceChief Financial OfficerShares withheld for tax-14,650$4.460$65 K261,107Form 4
filed Mary T. SzelaCEO and President, DirectorGrant or award+3,990$3.870$15 K1.08 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: TriSalus Life Sciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.3 M
6.6% of shares · 28.45 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-05-13 13:37 UTC, code LUDP, resumed 13:42 UTC
  • 2026-05-13 13:31 UTC, code LUDP, resumed 13:36 UTC

Fails to deliver

  • : 910 shares at $3.80
  • : 115 shares at $3.62
  • : 2,643 shares at $3.53
  • : 424 shares at $4.14
  • : 12 shares at $5.00

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

TriSalus Life Sciences, Inc. scorecard#

Passes 5 of the 17 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median5.0×Price to sales 5.0× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-8.1%Free cash flow is -8.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 4
    • ✓Revenue grew in the newest year53.4%Revenue up 53.4% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years53.8%53.8% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median53.8%53.8% a year against Healthcare's median of 8.5% (549 companies).
    • ✗Earnings per share grew in the newest year-1.84 vs -1.31Diluted EPS -1.84 in fiscal 2025 against -1.31 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-59.7%-59.7% against Healthcare's median of -7.7% (674 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-59.7%-59.7% in fiscal 2025 against -293.9% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.8×Current ratio 2.80 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-11.60Z-score -11.60 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year49.6%Diluted shares up 49.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from TriSalus Life Sciences, Inc.'s statements, beside the median of Healthcare.

TriSalus Life Sciences, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-59.7%-7.7%
Net margin-86.9%-8.1%
Revenue growth, 3 years a year53.8%8.5%
Revenue growth53.4%10.2%
Free cash flow margin-41.9%-1.3%

4of 9on the Piotroski tests of financial strength

  • Net loss of $39 million, the 4th loss-making year in a row.
  • Free cash flow was negative: -$19 million.
  • The share count rose 49.6% in the year.
  • Shareholders' equity is negative: -$34 million.

TriSalus Life Sciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

TriSalus Life Sciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021
Income statement
Revenue45291912—
Cost of revenue7.04.12.62.3—
Gross profit38251610—
Research and development151830r21—
Selling and marketing29261713—
General and administrative21182412r3.0
Operating income−27−36−54r−36r−3.0
Interest and finance income0.60.40.40.2r0.1
Interest expense and finance costs5.53.10.00.0—
Other non-operating income (expense)−0.5−0.3−0.4r8.97.8
Income before tax−39−30−59r−47r4.8
Income tax0.00.00.00.0r0
Net income including minority interests———5.54.8
Net income attributable to shareholders−39−30−59r−47r4.8
Earnings per share, basic-1.84-1.31-6.77r-161.55—
Earnings per share, diluted-1.84-1.31-6.77r-161.55—
Shares, weighted average (basic)38259.40.3—
Shares, weighted average (diluted)38259.40.3—
Balance sheet
Cash and cash equivalents208.5129.4r0.2
Receivables6.65.13.61.6—
Inventory3.14.02.51.5—
Current assets32212117r0.5
Property, plant and equipment1.81.72.12.2—
Right-of-use (leased) assets0.91.21.21.4—
Other intangible assets——0r0.8—
Total assets352425r22r251
Accounts payable3.02.33.44.9r1.1
Current liabilities11101532r1.6
Long-term debt33220——
Lease liabilities (non-current)1.21.31.2——
Total liabilities69505234r17
Retained earnings−331−280−250r−186r−17
Shareholders' equity−34−26−27r−177r−130r
Total liabilities and equity352425r22r251
Shares outstanding5031260.3—
Cash-flow statement
Depreciation and amortization0.60.70.7r0.4—
Share-based compensation9.15.41.40.4—
Cash from operating activities−18−41−51r−32r−1.7
Capital expenditure−0.9−0.3−0.6−0.7—
Intangible assets bought——0r−0.1—
Cash from investing activities−0.8−0.3−1.6r−1.8r0.1
Shares issued2215r0——
Shares bought back———−232—
Cash from financing activities31385513r0.5
Change in cash12−3.32.5−21r−1.1
Report10-K10-K10-K/A10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at TriSalus Life Sciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$4.8 M
Mary Szela
Other top executives, average
$2.5 M
the CEO earned 1.9× this
$100 invested is now
$83
TriSalus Life Sciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mary Szela$4.8 M$6.9 M$2.5 M$83
2024Mary T. Szela$4.1 M$1.5 M$1.8 M$59

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at TriSalus Life Sciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 10 · Material agreement 2 · New debt 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 12

TriSalus Life Sciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share saleResults announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
New debtUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of TriSalus Life Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2025$22 MPrivate placement after listing$10 to $50 million24equitySEC
Jun 2023$18 MPrivate placement after listing$10 to $50 million17equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by TriSalus Life Sciences, Inc.#

$360 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.

Lobbying, 2025
$360 K
#720 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$270 K
  • Medicare/Medicaid4 reports

Lobbying firms hired in 2025

Capitol Hill Consulting Group $360 K

TriSalus Life Sciences, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$270 K—3
2025$360 K—4
2024$390 K—7
2023$360 K—11
2022$240 K—9
2021$0—5
2020$40 K—4
2019$120 K—4
2018$180 K—2

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “TriSalus Life Sciences”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How TriSalus Life Sciences, Inc. compares in Healthcare

  • Market cap$234 M · higher than 36% of 2,013
  • Revenue$45 M · higher than 33% of 1,795
  • Net margin-56.6% · higher than 22% of 1,485
  • Revenue growth53.4% · higher than 83% of 1,003
  • Price / sales5.0× · lower than 39% of 1,071
  • FCF yield-8.1% · higher than 44% of 835
CompanyMarket capP/ENet marginRev. growth
TriSalus Life Sciences, Inc.🇺🇸$234 M—-56.6%+53.4%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at TriSalus Life Sciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show TriSalus Life Sciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about TriSalus Life Sciences, Inc.? Suggest a correction